View a list of resources dedicated to supporting your journey with cancer.
About Brain Tumors1
What is a brain tumor?
A brain tumor is a mass that forms from abnormal cell growth in the brain. There
are two basic types of tumors: primary and metastatic. Primary brain tumors originate
in the brain, whereas metastatic tumors are the result of a cancer that originated
elsewhere in the body and spread to the brain.
Benign versus malignant
When tumors are diagnosed, they are classified as benign or malignant. A benign
tumor is made up of very slow-growing cells that have distinct borders and rarely
spread. Benign brain tumors can be life threatening if they are located in a vital
area of the brain.
A malignant tumor often is rapid growing, invasive and life threatening. Malignant
brain tumors are referred to as brain cancer and rarely spread beyond the brain
and spinal cord.
The grade of a tumor
Tumors are assigned a grade to indicate the severity of the cancer. The grade assigned
depends on several factors, such as:
- Similarity of tumor cells to normal cells
- Rate of growth/indication of uncontrolled growth
- Dead (known as necrotic) cells in the center of the tumor
- The potential to invade or spread to surrounding tissue
- Blood supply to the tumor
Grade I tumors are the least severe and have the highest potential for survival.
Grade II tumors are still slow growing but have the potential to recur, sometimes
at a higher grade. A grade III tumor is malignant (cancerous) and has a high tendency
to recur at a higher grade. The most severe tumors are grade IV tumors. They are
able to form new blood vessels to help maintain their growth, and they have areas
of dead cells in their centers. Glioblastoma multiforme is the most common example
of a grade IV brain tumor.
High-grade malignant glioma
A glioma is a brain tumor that starts in certain cells called glial cells, which
are formed mainly from astrocytes. Astrocytes (named for their star-like shape)
form part of the supportive tissue in the brain and provide nutrients, support and
insulation for neurons. A high-grade tumor is malignant, life threatening, invasive
and usually fast growing.
Glioblastoma multiforme (GBM)
A glioblastoma multiforme is a grade IV malignant glioma. 30% of all primary brain
tumors are diagnosed as GBMs. These are the most aggressive of all gliomas. Get
a visual demonstration of the brain,
and learn about common
brain tumor symptoms.
References
Prescribing Information
Important Safety Information
GLIADEL Wafer should not be given to patients who have demonstrated a previous hypersensitivity
to carmustine or any of the components of GLIADEL Wafer.
Patients undergoing craniotomy for malignant glioma and implantation of GLIADEL
Wafer should be monitored closely for known complications of craniotomy, including
seizures, intracranial infections, abnormal wound healing, and brain edema. Cases
of intracerebral mass effect unresponsive to corticosteroids have been described
in patients treated with GLIADEL Wafer, including 1 case leading to brain herniation.
Carmustine, the active component of GLIADELWafer, can cause fetal harm when administered
to a pregnant woman. It is recommended that patients receiving GLIADEL Wafer discontinue
nursing.
Communication between the surgical resection cavity and the ventricular system should
be avoided to prevent the wafers from migrating into the ventricular system and
causing obstructivehydrocephalus. If a communication larger than the diameter of
a wafer exists, it should be closed prior to wafer implantation.
CT and MRI of the head may demonstrate enhancement in the brain tissue surrounding
the resection cavity after implantation of GLIADEL Wafer. This enhancement may represent
edema and inflammation caused by GLIADEL Wafer or tumor progression.
The short-term and long-term toxicity profiles of GLIADEL Wafer when given in conjunction
with chemotherapy have not been fully explored.
The following 4 categories of adverse events are possibly related to treatment with
GLIADEL Wafer:
Seizures: In the initial surgery trial, the incidence of seizures was 33.3%
in patients receiving GLIADEL Wafer and 37.5% in patients receiving placebo. Grand
mal seizures occurred in 5% of GLIADEL Wafer–treated patients and 4.2% of placebo-treated
patients. The incidence of seizures within the first 5 days after wafer implantation
was 2.5% in the GLIADEL Wafer group and 4.2% in the placebo group.
In the surgery for recurrent disease trial, the incidence of post-operative seizures
was 19% in both patients receiving GLIADEL Wafer and placebo. In this study, 12/22
(54%) of patients treated with GLIADEL Wafer and 2/22 (9%) of placebo patients experienced
the first new or worsened seizure within the first 5 post-operative days.
The median time to onset of the first new or worsened post-operative seizure was
3.5 days in patients treated with GLIADEL Wafer and 61 days in placebo patients.
Brain Edema: In the initial surgery trial, brain edema was noted in 22.5%
of patients treated with GLIADEL Wafer and 19.2% of patients treated with placebo.
Development of brain edema with mass effect (due to tumor recurrences, intracranial
infection, or necrosis) may necessitate re-operation and, in some cases, removal
of GLIADEL Wafer or its remnants.
Healing Abnormalities: The following healing abnormalities have been reported
in GLIADEL Wafer clinical trials: wound dehiscence, delayed wound healing, subdural,
subgaleal or wound effusions, and cerebrospinal fluid leak. In the initial surgery
trial, healing abnormalities occurred in 15.8% of GLIADEL Wafer–treated patients
and in 11.7% of placebo recipients. Cerebrospinal fluid leaks occurred in 5% of
GLIADEL Wafer recipients and 0.8% of those given placebo.
During surgery, a water-tight dural closure should be obtained to minimize the risk
of cerebrospinal fluid leak. In the surgery for recurrent disease trial, the incidence
of healing abnormalities was 14% in GLIADEL Wafer–treated patients and 5% in patients
receiving placebo wafers.
Intracranial Infection: In the initial surgery trial, the incidence of brain
abscess or meningitis was 5% in patients treated with GLIADEL Wafer and 6% in patients
receiving placebo. In the recurrent setting, the incidence of brain abscess or meningitis
was 4% in GLIADEL Wafer patients and 1% in patients receiving placebo.
Please see full Prescribing Information.
|
|
|
This Web site contains information relating to various medical conditions and their treatment. Such information is provided for educational purposes only and is not meant to substitute the advice of a physician or other health care professional.
You should not use this information for diagnosing a health problem or disease. Only your doctor can assess the benefits and risks of therapy to determine whether a medication is right for you. You should discuss any questions about you or your loved one’s personal medical needs with your doctor.
The laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country.
The information provided in this Web site is intended for residents of the United States only. The products discussed herein may have different product labeling in different countries.